Abstract
Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.1182/blood.v122.21.1496.1496
Journal: Blood | Publication Date: Nov 15, 2013 |
Citations: 5 |
Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs)
Join us for a 30 min session where you can share your feedback and ask us any queries you have